Related Experiment Video
Updated: May 30, 2026
08:57
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
Published on: March 26, 2015
Targeting synaptic pathology in multiple sclerosis: fingolimod to the rescue?
1School of Biomedical Sciences, College of Medicine & Veterinary Medicine, University of Edinburgh, Edinburgh, UK. t.gillingwater@ed.ac.uk
British Journal of Pharmacology
|August 3, 2011
Summary
Fingolimod, an immunomodulatory drug, may treat multiple sclerosis (MS) by improving synaptic dysfunction. This study in EAE mice showed fingolimod reversed glutamatergic transmission issues and reduced spine loss, suggesting benefits for MS synaptic pathology.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a central nervous system inflammatory disorder characterized by demyelination and neurodegeneration.
- Synaptic dysfunction is increasingly recognized as a key component in MS pathogenesis.
- Fingolimod (FTY720) is an orally active immunomodulatory drug showing therapeutic potential in MS.
Purpose of the Study:
- To investigate the potential of fingolimod in ameliorating synaptic dysfunction in a mouse model of MS.
- To explore the effects of fingolimod on glutamatergic transmission and dendritic spine morphology in experimental autoimmune encephalomyelitis (EAE) mice.
Main Methods:
- Utilized the EAE mouse model to mimic MS.
- Assessed glutamatergic transmission modifications in the striatum.
- Quantified dendritic spine loss in affected neurons.
Main Results:
- Fingolimod treatment reversed alterations in glutamatergic transmission in EAE mice.
- Fingolimod administration led to a reduction in the severity of dendritic spine loss.
- These findings suggest fingolimod impacts synaptic pathology in MS.
Conclusions:
- Fingolimod demonstrates beneficial effects on synaptic pathology in MS, potentially by targeting synaptic dysfunction.
- This suggests fingolimod may be a valuable therapeutic agent for MS and potentially other neurological disorders involving inflammation and synaptic pathology.
